New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused ...

ZUMA-2 cohorts drive brexu-cel’s journey in relapsed/refractory mantle cell lymphoma, from high response rates to dose ...

Researchers assessed the safety and efficacy of the novel PolaR-ICE regimen among patients with relapsed or refractory DLBCL in the second-line setting.

The TGA registration establishes Minjuvi as the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for this group of patients. 2 ...

Preclinical data showed enhanced anti-tumor activity and reduced cytokine release compared to conventional single-chain CAR T approaches -- Early clinical case from CELESTIAL-301 trial, the ...

Delivery of TPST-2003 lentiviral vector to Cincinnati Children’s Applied Gene and Cell Therapy Center enables manufacturing activities required ...

The objective response rate was 70%, with 45% of patients achieving a complete response or better. The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic ™ (linvoseltamab ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

Legend, like Kelonia, develops and manufactures cell therapies to treat life-threatening diseases, particularly cancer. ・Legend is best known for Carvykti, a CAR-T treatment for relapsed or refractory ...

PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in R/R High-Risk Myelodysplastic Syndrome & R/R Acute Myeloid Leukemia ...

Panelists discuss how strategic sequencing decisions in frontline CLL therapy, informed by new evidence from the Rhodes et al. ASH 2024 study, have downstream implications for managing treatment ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The good news, I guess, is that we have ...